Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen

Journal of Clinical Oncology

Volumn 21, Issue 10, 2003, Pages 1967-1972

  Lipton, Allan ^a   Ali, S M ^a   Leitzel, K ^a   Demers, L ^a   Harvey, H A ^a   Chaudri Ross, H A ^a   Brady, C ^a   Wyld, P ^a   Carney, W ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LETROZOLE; TAMOXIFEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; NITRILE; TRIAZOLE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME; ADULT; AGED; BLOOD; BREAST TUMOR; CANCER STAGING; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASM; PATHOLOGY; PHASE 3 CLINICAL TRIAL; SWITZERLAND; TUMOR RECURRENCE; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; RECEPTOR, ERBB-2; SWITZERLAND; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES; UNITED STATES;

EID: 0038011944     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.09.098     Document Type: Article

References (22)

1. Maguire HC, Greene MI: The neu (c-erbB-2) oncogene. Semin Oncol 16:148-155, 1989
2. Lupu R, Lippman ME: The role of erbB-2 signal transduction pathways in human breast cancer. Breast Cancer Res Treat 27:83-93, 1993
3. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
4. Clark GM, McGuire WL: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51:944-948, 1991
5. Mori S, Mori Y, Mukaiyama T, et al: In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells. Jpn J Cancer Res 81:489-494, 1990
6. Carney WP, Hamer PJ, Petit D, et al: Detection and quantitation of the human neu oncoprotein. J Tumor Marker Oncol 6:53-72, 1991
7. Langton BC, Crenshaw MC, Chao LA, et al: An antigen immunologically related to the external domain of gp 185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene. Cancer Res 51:2593-2598, 1991
8. Wright C, Angus B, Nicholson S, et al: Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 49:2087-2090, 1989
9. Lipton A, Ali SM, Leitzel K, et al: Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20:1467-1472, 2002
10. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001
11. International Union Against Cancer: Manual of adult and pediatric medical oncology, in Monfardini S, Brunner K, Crowther D, et al (eds): Evaluation of the Cancer Patient and the Response to Treatment. Berlin, Germany, Springer, 1987, pp 22-38
12. Schwartz MK, Smith C, Schwartz DC, et al: Monitoring therapy by serum HER-2/neu. Int J Biol Markers 5:324-329, 2000
13. Benz CC, Scott GK, Sarup JC, et al: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-95, 1993
14. Liu Y, el-Ashry D, Chen D, et al: MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 34:97-117, 1995
15. Pietras R. Arboleda J, Reese D, et al: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446, 1995
16. Wong WL, Bajamonde A, Nelson B, et al: Baseline serum HER2 (sHER2) levels in pivotal herceptin breast cancer trials: A comparison of 2 ELISA methods. Proc Am Soc Clin Oncol 19:77a, 2000 (abstr 297)
17. Ellis M, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1 and/or erbB-2 positive, estrogen-receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
18. Read LD, Keith D Jr, Slamon DJ, et al: Hormonal modulation of HER-2/neu proto-oncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cells lines. Cancer Res 50:3947-3951, 1990
19. Colomer R, Saceda M, Martin BM, et al: Cross-regulation of erbB2 oncoprotein and estrogen receptor by estrogen and the erbB2 ligands (gp30/p75). Proc Am Assoc Cancer Res 33:82, 1992 (abstr 494)
20. Kato S, Endoh H, Masuhiro Y, et al: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494, 1995
21. Bunone G, Briand PA, Miksicek RJ, et al: Activation of the unliganded estrogen receptor by EGF involves the MAPKinase pathway and direct phosphorylation. EMBO J 15:2174-2183, 1996
22. Witters L, Kumar R, Chinchilli V, et al: Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2/neu antibody. Breast Cancer Res Treat 42:1-5, 1997